Drug class
Antiviral-HIV (Antiretroviral) Nonnucleoside RT Inhibitor
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) constitute an essential class of antiretroviral medications utilized primarily for the management and treatment of human immunodeficiency virus type 1 (HIV-1) infection. Read more about Antiviral-HIV (Antiretroviral) Nonnucleoside RT Inhibitor
46 drugs in this class 24 manufacturers
Drugs in Antiviral-HIV (Antiretroviral) Nonnucleoside RT Inhibitor
EFAVIRENZ
EFAVIRENZ
SYMFI LO (efavirenz/lamivudine/tenofovir disoproxil fumarate)
SYMFI (efavirenz/lamivudine/tenofovir disoproxil fumarate)
NEVIRAPINE
NEVIRAPINE ER (nevirapine)
EFAVIRENZ
EFAVIRENZ
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) constitute an essential class of antiretroviral medications utilized primarily for the management and treatment of human immunodeficiency virus type 1 (HIV-1) infection.
They function through non-competitive, allosteric binding to an allosteric pocket adjacent to the active catalytic site of the HIV-1 reverse transcriptase enzyme.
This binding induces a conformational change that arrests enzyme activity, halting the reverse transcription of viral single-stranded RNA into double-stranded proviral DNA and preventing viral replication within host immune cells.
Clinically, these agents—such as efavirenz, rilpivirine, etravirine, and doravirine—serve as critical components of combination antiretroviral therapy (cART) regimens to achieve sustained virologic suppression and preserve immune function.
-
nih.gov
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) constitute an essential class of antiretroviral medications utilized primarily for the management and treatment of human immunodeficiency virus type 1 (HIV-1) infection
-
nih.gov
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) constitute an essential class of antiretroviral medications utilized primarily for the management and treatment of human immunodeficiency virus type 1 (HIV-1) infection This binding induces a conformational change that arrests enzyme activity, halting the reverse transcription of viral single-stranded RNA into double-stranded proviral DNA and preventing viral replication within host immune cells
-
fda.gov
They function through non-competitive, allosteric binding to an allosteric pocket adjacent to the active catalytic site of the HIV-1 reverse transcriptase enzyme
-
nih.gov
They function through non-competitive, allosteric binding to an allosteric pocket adjacent to the active catalytic site of the HIV-1 reverse transcriptase enzyme Clinically, these agents—such as efavirenz, rilpivirine, etravirine, and doravirine—serve as critical components of combination antiretroviral therapy (cART) regimens to achieve sustained virologic suppression and preserve immune function
-
hiv.gov
This binding induces a conformational change that arrests enzyme activity, halting the reverse transcription of viral single-stranded RNA into double-stranded proviral DNA and preventing viral replication within host immune cells
-
iapac.org
This binding induces a conformational change that arrests enzyme activity, halting the reverse transcription of viral single-stranded RNA into double-stranded proviral DNA and preventing viral replication within host immune cells Clinically, these agents—such as efavirenz, rilpivirine, etravirine, and doravirine—serve as critical components of combination antiretroviral therapy (cART) regimens to achieve sustained virologic suppression and preserve immune function
-
hivguidelines.org
Clinically, these agents—such as efavirenz, rilpivirine, etravirine, and doravirine—serve as critical components of combination antiretroviral therapy (cART) regimens to achieve sustained virologic suppression and preserve immune function
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.